Novel Biology-Informed Diagnostic Framework
This section proposes an updated diagnostic framework that synthesizes current pathophysiological understanding with clinical reality. Unlike existing criteria that treat ME/CFS as a single homogeneous entity, this three-tiered approach recognizes disease heterogeneity while maintaining diagnostic precision.
1 Rationale for a New Framework
1.1 The Logic Chain: From Biology to Diagnosis
The three-tiered diagnostic framework follows logically from four fundamental observations about ME/CFS:
Observation 1: ME/CFS is a Clinical Syndrome with a Core Pathognomonic Feature
Post-exertional malaise (PEM) with delayed onset, disproportionate severity, and prolonged recovery distinguishes ME/CFS from other major fatiguing conditions, including depression and deconditioning. This symptom:
- Cannot be explained by deconditioning (which improves with gradual activity)
- Cannot be explained by depression (which may improve somewhat with activity)
- Has objective correlates (2-day CPET showing Day 2 deterioration (Lim et al. 2020) (Keller et al. 2024))
- Reflects underlying cellular energy failure (ATP depletion (Heng et al. 2025) (Syed et al. 2025))
Logical consequence: Tier 1 must retain syndrome-based diagnosis with PEM as mandatory criterion, ensuring we capture the defining pathophysiology while maintaining compatibility with existing frameworks.
Observation 2: ME/CFS Heterogeneity Reflects Multiple Causal Pathways, Not Measurement Error
The failure of single-target treatments in randomized controlled trials does not mean “ME/CFS has no biological basis”—it means we are mixing biologically distinct subgroups:
- Rituximab (anti-CD20 B cell depletion) failed in large trials (Fluge et al. 2015) despite initial promise
- Daratumumab (anti-CD38 plasma cell depletion) succeeded in 60% of patients in pilot study (Fluge et al. 2025)
- Interpretation: Not “autoimmunity isn’t involved,” but rather “wrong cell type targeted” (short-lived B cells vs. long-lived plasma cells) AND “only a subset has autoimmune-driven disease”
- Evidential asymmetry: The negative rituximab RCT (Fluge et al. 2015) provides stronger disconfirmation of B-cell depletion as a general ME/CFS strategy than the daratumumab pilot provides confirmation of plasma-cell targeting; daratumumab findings require replication in controlled trials before clinical inference is warranted.
The Heng 2025 study (Heng et al. 2025) demonstrated that a 7-biomarker panel spanning three systems (energy, immune, vascular) achieved 91% diagnostic accuracy. This implies:
- All three systems are coordinately dysfunctional (not independent)
- ME/CFS is not six separate diseases but one syndrome with six co-occurring mechanisms
- Treatment must address multiple domains simultaneously
Logical consequence: Tier 2 must assess all relevant biological domains and document which are present, rather than forcing patients into exclusive categories. The question is not “Is this autoimmune OR metabolic ME/CFS?” but “Which of the six domains show dysfunction in this patient?”
Observation 3: Treatment Response Depends on Rate-Limiting Steps, Not Just Presence of Pathology
Consider two patients, both with elevated GPCR autoantibodies and mitochondrial dysfunction:
- Patient A: Autoantibodies are driving ongoing inflammation → mitochondria are secondarily impaired → removing autoantibodies allows mitochondrial recovery → daratumumab produces dramatic improvement
- Patient B: Initial autoimmune trigger has resolved, but mitochondrial damage is now self-perpetuating (WASF3 accumulation, cristae disruption) → removing residual autoantibodies doesn’t help because mitochondria cannot recover → daratumumab fails
Both patients are “autoantibody-positive,” but only Patient A responds. The difference: which domain is rate-limiting (the bottleneck preventing recovery).
This explains:
- Why daratumumab works in 60% not 100% of patients (Fluge et al. 2025)
- Why low baseline NK cell count predicted non-response (suggests irreversible immune exhaustion)
- Why biomarker-positive patients don’t uniformly respond to biomarker-targeted treatments
Logical consequence: Tier 2 must enable multi-target treatment protocols. We cannot predict a priori which domain is rate-limiting, so we must:
- Treat all accessible, low-risk domains simultaneously (“quick wins”)
- Reassess at 3–6 months to identify which domains responded vs. persisted
- Intensify treatment for persistent domains (these are likely rate-limiting)
Observation 4: ME/CFS Has Irreversible Thresholds, Making Timing Critical
The natural history literature (Maksoud et al. 2020) and patient reports converge on temporal patterns:
- 6 months: If symptoms persist beyond 6 months, spontaneous resolution becomes unlikely (transition from “post-viral fatigue” to “established ME/CFS”)
- 2 years: Around 2 years, disease transitions from early (hypermetabolic, potentially reversible) to established (hypometabolic, epigenetically locked) state
- Cumulative crashes: Repeated PEM episodes cause progressive damage; there may be a threshold (5–10 severe crashes) beyond which recovery capacity is permanently impaired
- Rolling PEM: In severe patients, individual crashes may overlap without full stabilization between episodes — a phenomenon documented in clinical care guides where the functional floor ratchets downward continuously rather than stepwise (Hermisson et al. 2026). This pattern makes recovery estimation unreliable because physiological recovery time is reset by each new crash before the previous one resolves, creating a state of chronic physiological crisis.
- 25% severe: One-quarter of ME/CFS patients become housebound/bedbound, most starting with mild disease
The progression from mild to severe appears preventable in many cases through aggressive pacing, yet existing diagnostic criteria provide no framework for:
- Identifying patients at high risk of progression
- Defining what “aggressive pacing” means operationally
- Communicating urgency of intervention before crossing irreversible thresholds
Logical consequence: Tier 3 must prospectively assess progression risk and provide actionable intervention protocols. The diagnostic framework must be dynamic (tracking trajectory) not static (labeling current state).
1.2 Why Three Tiers? Why Not Two or Four?
The three-tiered structure reflects three distinct clinical questions:
- Tier 1 (Syndrome): Does this patient have ME/CFS? (Yes/No based on universal clinical features)
- Tier 2 (Biology): Which pathophysiological mechanisms are driving this patient’s disease? (Multi-label classification across 6 domains)
- Tier 3 (Trajectory): How severe is the disease currently, and what is the risk of irreversible progression? (Severity + prospective risk)
These cannot be collapsed:
- Tier 1 alone (current criteria) misses treatment stratification and progression prevention
- Tier 2 alone (biology-only) would miss patients without access to biomarkers and wouldn’t address progression risk
- Tier 3 alone (severity-only) would lack diagnostic specificity and treatment guidance
Each tier serves a distinct purpose and requires different information.
1.3 Limitations of Existing Criteria
Existing diagnostic criteria (Fukuda, Canadian Consensus, ICC, IOM) share important limitations that this framework addresses:
- Syndrome-based only: Rely exclusively on symptom constellations without biological stratification, preventing precision medicine
- Static classification: Diagnose a point-in-time state without assessing progression risk, missing the 25% who will become severe
- Assume homogeneity: Force heterogeneous patients into single diagnostic category, explaining why single-target trials fail
- Limited treatment guidance: Diagnosis doesn’t inform which interventions to prioritize, leading to trial-and-error
- Miss therapeutic windows: Fail to identify the 6-month and 2-year critical intervention windows
1.4 How Recent Advances Enable This Framework
The proposed three-tiered framework would not have been possible a decade ago. Recent advances now make it feasible:
- Objective biomarkers: GPCR autoantibodies (Loebel et al. 2016) (Bynke et al. 2020), Heng 7-marker panel (Heng et al. 2025), 2-day CPET (Lim et al. 2020) (Keller et al. 2024) provide biological stratification
- Mechanistic understanding: Autoimmunity (Fluge et al. 2025), mitochondrial dysfunction (Wang et al. 2023) (Syed et al. 2025), neuroinflammation (Nakatomi et al. 2014) explain heterogeneity
- Treatment stratification proof-of-concept: Daratumumab 60% response in autoimmune subset (Fluge et al. 2025), immunoadsorption for GPCR autoantibodies (Stein et al. 2025) demonstrate that biomarker-guided treatment works
- Natural history data: Critical intervention windows (Maksoud et al. 2020), progression patterns (Chu et al. 2019), cumulative damage model supported by natural history data
The proposed framework integrates these advances into clinically actionable diagnostic tiers.
1.5 Summary: The Logical Structure
Premise 1: ME/CFS is a clinical syndrome with a pathognomonic feature (PEM) that has objective correlates
⇒ Tier 1: Syndrome-based diagnosis with PEM mandatory
Premise 2: ME/CFS heterogeneity reflects multiple co-occurring biological mechanisms; treatment response depends on which mechanism is rate-limiting
⇒ Tier 2: Multi-domain biological phenotyping to enable multi-target treatment
Premise 3: ME/CFS has irreversible thresholds (6 months, 2 years, cumulative crashes); progression to severe disease is often preventable
⇒ Tier 3: Severity classification + prospective risk assessment with emergency protocols
The three-tiered structure is not arbitrary—it reflects the clinical necessity of answering three distinct clinical questions (diagnosis, mechanism, trajectory) that cannot be collapsed without losing critical information. ## Tier 1: Clinical Syndrome Criteria {#subsec-tier1}
Tier 1 establishes the diagnosis of ME/CFS based on clinical features. These criteria are universal—all patients must meet Tier 1 to receive the diagnosis.
1.6 Core Diagnostic Features (All Required)
Post-exertional malaise must be present with ALL of the following characteristics:
- Delayed onset: Symptom exacerbation occurs 12–72 hours after triggering activity (not immediately)
- Disproportionate severity: Minimal exertion produces profound symptom worsening far beyond normal fatigue
- Multi-domain triggers: Symptoms triggered by physical exertion AND cognitive exertion AND emotional exertion
- Prolonged recovery: Symptom exacerbation persists \(>\) 24 hours (mild cases) to weeks or months (severe cases)
Objective verification (optional but supportive): Two-day cardiopulmonary exercise testing showing Day 2 deterioration: workload at ventilatory threshold decreases \(\geq\) 20% on Day 2 compared to Day 1 (Lim et al. 2020) (Keller et al. 2024).
Patients must demonstrate chronic energy deficit characterized by:
- Morning depletion: Waking already exhausted despite sleep duration
- Disproportionate activity cost: Activities of daily living (hygiene, eating, sitting upright) consume excessive energy relative to effort
- No functional reserve: Zero capacity to handle unexpected physical, cognitive, or emotional demands
- Effort-performance disconnect: Subjective experience of maximal effort producing minimal objective output (a phenomenon that distinguishes ME/CFS from deconditioning or primary depression)
The effort-performance disconnect represents a novel diagnostic criterion capturing the lived experience of ME/CFS: patients describe “giving everything” to accomplish minimal tasks, feeling as though simple activities require marathon-level exertion while producing negligible results (Strassheim, Newton, and Collins 2021) (Fennell, Dorr, and George 2021).
Duration: Symptoms must persist \(\geq\) 6 months
Rationale: Six-month persistence indicates transition from post-viral fatigue (which typically resolves) to established ME/CFS with aberrant pathophysiology (Maksoud et al. 2020)
Exclusions: Symptoms not better explained by:
- Active medical conditions (untreated hypothyroidism, sleep apnea, anemia, malignancy)
- Primary psychiatric disorders (though secondary depression/anxiety are common and do not exclude ME/CFS)
- Medication side effects
Important: Comorbid conditions that are part of the ME/CFS disease spectrum (POTS, fibromyalgia, MCAS, IBS) do not exclude the diagnosis—these represent overlapping pathophysiology rather than alternative explanations.
1.7 Supporting Features (≥3 of 5 Required)
In addition to the three core features, patients must have at least three of the following five supporting features:
Unrefreshing Sleep
- Sleep that fails to restore energy regardless of duration
- Waking feeling as exhausted as when going to bed
- Present in 95–100% of ME/CFS patients (Jason et al. 2014) (Unger, Lin, Brimmer, Lapp, Komaroff, Nath, Jones, et al. 2016)
Cognitive Impairment
- Processing speed deficits (most robust finding: Hedges’ g = -0.82) (Cvejic, Birch, and Vollmer-Conna 2022)
- Attention and working memory impairment
- Word-finding difficulties, linguistic reversals
- Brain fog that is not attributable to fatigue or depression (Unger et al. 2024)
Autonomic Dysfunction
- Orthostatic intolerance: symptoms worsened by upright posture
- POTS (heart rate increase \(\geq\) 30 bpm upon standing), orthostatic hypotension, or neurally mediated hypotension
- Temperature dysregulation, inappropriate sweating or lack of sweating
- Present in 70–90% of ME/CFS patients (Newton et al. 2007)
Pain
- Myalgia (muscle pain), particularly with post-exertional exacerbation
- Arthralgia (joint pain, characteristically migratory without inflammation)
- Headaches (migraine or tension-type) (Ravindran et al. 2011)
- Pain present in \(\sim\) 80% of patients (Unger, Lin, Brimmer, Lapp, Komaroff, Nath, Larusso, et al. 2016)
Sensory Hypersensitivity
- Photophobia (light sensitivity requiring sunglasses indoors or dimmed environment)
- Phonophobia (sound sensitivity; normal volumes feel uncomfortable)
- Chemical sensitivity (fragrances, cleaning products, exhaust)
- Touch hypersensitivity or allodynia
- Present in 70–90% of patients (Jason et al. 2013)
Tier 1 criteria establish ME/CFS as a clinical syndrome with mandatory post-exertional malaise, baseline energy insufficiency, and 6-month duration. Supporting features (sleep, cognition, autonomic, pain, sensory) must be present in sufficient number (\(\geq\) 3 of 5) to confirm the characteristic multi-system presentation. These criteria are compatible with existing frameworks (Canadian Consensus, ICC, IOM) but add explicit recognition of the effort-performance disconnect and specify the 6-month threshold as marking transition to established disease. ## Tier 2: Biological Phenotyping (Multi-Domain Assessment) {#subsec-tier2}
Once Tier 1 criteria are met, patients should undergo comprehensive biological phenotyping to identify which pathophysiological domains are involved. This enables targeted treatment and research stratification.
1.8 Rationale: Co-Occurrence Rather Than Predominance
Critical insight: ME/CFS patients typically have dysfunction in multiple biological domains simultaneously. The Heng 2025 study demonstrated that a 7-biomarker panel spanning energy metabolism, immune function, and vascular endothelium achieved 91% diagnostic accuracy precisely because all three systems show coordinated dysfunction (Heng et al. 2025). This finding validates the multi-lock model (Chapter Speculative Mechanistic Hypotheses): ME/CFS persists because multiple self-reinforcing pathophysiological processes operate concurrently.
Certainty: 0.50. This certainty reflects convergent observational evidence that most ME/CFS patients show abnormalities across multiple biological systems; it does not imply that causal interdependence between domains has been established. ME/CFS should be understood as a syndrome with six co-occurring, mutually reinforcing biological domains. Most patients have abnormalities in \(\geq\) 3 domains:
- Autoimmune features: 30–60% (GPCR autoantibodies (Loebel et al. 2016) (Bynke et al. 2020))
- Mitochondrial/metabolic dysfunction: 70–95% (ATP abnormalities (Heng et al. 2025), lactate elevation (Lien et al. 2019))
- Neuroinflammation/central sensitization: 70–90% (central sensitization 84% (Nijs et al. 2021), sensory sensitivities 70–90% (Jason et al. 2013))
- Dysautonomia: 70–90% (POTS 25–50%, broader orthostatic intolerance 70–90% (Newton et al. 2007))
- Endothelial dysfunction: Prevalence unknown (Heng 2025 documented elevation in ME/CFS cohort (Heng et al. 2025))
- Mast cell / histaminergic dysregulation: 16–25% meet MCAS features (Rohrhofer et al. 2025); associated with significantly higher orthostatic intolerance rates (89% vs. 72%, \(p < 0.0001\))
These domains are interdependent:
- Autoimmunity (GPCR autoantibodies) → Mitochondrial dysfunction (\(\beta_2\)-adrenergic signaling regulates mitochondrial biogenesis)
- Mitochondrial dysfunction (ATP depletion) → Neuroinflammation (danger signal release, ionic gradient failure)
- Endotheliopathy (impaired vasodilation) → Dysautonomia (orthostatic intolerance, cerebral hypoperfusion)
- Neuroinflammation (cytokine production) → Autoimmunity (B cell activation)
- Mast cell activation (histamine, VEGF, PGD2) → Dysautonomia (baroreceptor impairment at carotid bodies, preload failure via histamine-mediated vasodilation) and Neuroinflammation (VEGF-driven blood–brain barrier disruption) (Theoharides, Twahir, and Kempuraj 2024)
Treatment targeting a single domain may fail because untreated domains maintain dysfunction. The multi-domain model predicts that:
- Patients with more domains affected will have worse outcomes
- Multi-target interventions will outperform single-target interventions
- Treatment response requires both (a) presence of dysfunction in a domain AND (b) that domain being rate-limiting (the bottleneck gating recovery)
1.9 Domain 1: Autoimmune Features
Assessment:
- GPCR autoantibodies (\(\beta_2\)-adrenergic, M3 muscarinic, M4 muscarinic) above age/sex-matched reference ranges (Loebel et al. 2016) (Bynke et al. 2020)
- ANA (any titer; present in 20–30% ME/CFS vs. 5–10% healthy controls)
- Plasma cell expansion on flow cytometry (CD38+CD138+ if available)
- Low NK cell cytotoxicity (impaired killing assay) and/or low NK cell count (<5th percentile) with normal total lymphocytes — note that count and cytotoxic function are distinct measurements that can be impaired independently
If Present → Diagnosis: “ME/CFS with Autoimmune Component”
Treatment Implications:
- Candidate for immunoadsorption (IgG removal) (Stein et al. 2025)
- Candidate for daratumumab (anti-CD38, depletes plasma cells) (Fluge et al. 2025)
- Candidate for BC007 (GPCR autoantibody neutralizer) (Hohberger et al. 2021)
- Monitor for worsening with immune-stimulating interventions
Prevalence: 30–60% of ME/CFS patients
1.10 Domain 2: Mitochondrial/Metabolic Dysfunction
Assessment:
- Heng 7-marker panel (if available): Elevated AMP, ADP (energy depletion arm) (Heng et al. 2025)
- Elevated lactate: Resting >2.0 mmol/L or abnormal accumulation during 2-day CPET (Lien et al. 2019)
- ATP profile abnormalities (if specialized testing available)
- WASF3 elevation on skeletal muscle biopsy (if indicated for severe cases) (Wang et al. 2023)
If Present → Diagnosis: “ME/CFS with Mitochondrial Dysfunction”
Treatment Implications:
- CoQ10 (ubiquinol 200–400 mg/day)
- NAD+ precursors (nicotinamide riboside 1000–2000 mg/day, treatment duration \(\geq\) 10 weeks)
- D-ribose, B-complex vitamins, alpha-lipoic acid, PQQ
- Strict pacing critical (ATP depletion is cumulative)
- Heart rate monitoring (stay below 60% maximum heart rate during activity)
Prevalence: 70–95% (virtually all ME/CFS patients show some degree of energy metabolism dysfunction)
1.11 Domain 3: Neuroinflammation/Central Sensitization
Assessment:
Research settings: PET evidence of microglial activation (Nakatomi et al. 2014), fMRI showing altered temporoparietal junction or salience network connectivity (Walitt et al. 2024) (Shan et al. 2020)
Clinically accessible:
- Central sensitization confirmed by quantitative sensory testing: pressure pain thresholds <5th percentile at \(\geq\) 3 standardized sites (Nijs et al. 2021)
- Small fiber neuropathy: skin biopsy showing intraepidermal nerve fiber density <5th percentile (Oaklander et al. 2022)
- Severe sensory sensitivities requiring environmental modification (inability to tolerate normal lighting, sound levels, or chemical exposures)
If Present → Diagnosis: “ME/CFS with Neuroinflammatory Component”
Treatment Implications:
- Low-dose naltrexone (LDN 1.5–4.5 mg at bedtime)
- Environmental modification (dimmed lighting, noise reduction, fragrance-free environment)
- IVIG (if small fiber neuropathy documented and insurance approves)
- Avoid activities that trigger sensory overload (cognitive post-exertional malaise)
Prevalence: 70–90% (sensory sensitivities 70–90%, central sensitization 84%, small fiber neuropathy 30–38%)
1.12 Domain 4: Dysautonomia
Assessment:
- Gold standard: Tilt table testing showing POTS (heart rate increase \(\geq\) 30 bpm within 10 minutes), orthostatic hypotension (blood pressure drop \(\geq\) 20/10 mmHg), or neurally mediated hypotension
- Clinically accessible: NASA Lean Test (10-minute standing test; positive if heart rate increases \(\geq\) 30 bpm)
- Heart rate variability analysis (reduced HRV indicating sympathetic dominance)
- QSART/thermoregulatory sweat test (if available)
If Present → Diagnosis: “ME/CFS with Dysautonomia”
Treatment Implications:
Volume expansion: 3–10 g sodium + 2–3 L fluids daily
Compression garments (20–30 mmHg waist-high or thigh-high)
Pharmacological:
- Fludrocortisone 0.05–0.2 mg daily
- Midodrine 2.5–10 mg three times daily
- Ivabradine 2.5–7.5 mg twice daily
- Low-dose beta-blockers (propranolol 10–20 mg as needed)
Positional strategies: elevate head of bed, avoid prolonged standing, sit when possible
Prevalence: 70–90% (POTS 25–50%, broader orthostatic intolerance 70–90%)
1.13 Domain 5: Endothelial Dysfunction
Assessment:
Heng 7-marker panel (if available): Elevated von Willebrand factor, fibronectin, thrombospondin-1 (endothelial activation arm) (Heng et al. 2025)
Clinical markers of microvascular dysfunction:
- Livedo reticularis (mottled skin discoloration)
- Raynaud’s phenomenon (cold-induced color changes in fingers/toes)
- Delayed capillary refill (>3 seconds)
Cerebral hypoperfusion on SPECT imaging (if available)
If Present → Diagnosis: “ME/CFS with Endothelial Dysfunction”
Treatment Implications (experimental):
- L-citrulline 3–6 g/day or L-arginine (for nitric oxide production)
- Omega-3 fatty acids (EPA/DHA 2–4 g/day) — rationale is mechanistic (anti-inflammatory resolvins, NO-mediated vasodilation); no ME/CFS RCT evidence. Note: a 2026 study found EPA accumulation impairs vascular repair after mechanical brain trauma (TBI/CTE context); this harm mechanism does not apply to ME/CFS endothelial dysfunction, which involves chronic inflammation and reduced nitric oxide (\(\text{NO}\)) bioavailability rather than post-traumatic angiogenic repair (Karakaya et al. 2026).
- Low-dose aspirin 81 mg daily (if no contraindications)
- Emerging research: anticoagulation trials, fibrinolytic protocols (investigational only)
Prevalence: Unknown (Heng 2025 documented elevation in ME/CFS cohort; prevalence in broader ME/CFS population requires validation)
1.14 Domain 6: Mast Cell / Histaminergic Dysregulation
Assessment:
Mast cell activation syndrome (MCAS) is present in approximately 16–25% of ME/CFS patients (Rohrhofer et al. 2025) and is strongly associated with orthostatic intolerance (89% vs. 72% without MCAS, \(p < 0.0001\)). Perivascular mast cells at carotid bodies, hypothalamic nuclei, and cardiac ganglia are anatomically positioned to act as upstream triggers for dysautonomia: corticotropin-releasing hormone (CRH) activates hypothalamic mast cells, triggering release of VEGF, tryptase, and neurotensin that disrupt the blood–brain barrier and impair baroreceptor reflex function (Theoharides, Twahir, and Kempuraj 2024).
Domain 6 requires \(\geq\) 2 of the following:
- Episodic multi-system symptoms: Recurring episodes involving \(\geq\) 2 organ systems (skin flushing/urticaria, gastrointestinal cramping/diarrhea, neurological brain fog/headache, cardiovascular palpitations/hypotension)
- Elevated urinary mast cell mediators: 24-hour urine N-methylhistamine \(>\) 1.29\(\\times\) upper normal limit, or LTE4 \(>\) 1.36\(\\times\) upper normal limit, or prostaglandin D2 metabolite elevated; collected during a symptomatic period (Lee and Picard 2025)
- Reactive serum tryptase: Acute draw within 4 hours of symptomatic episode showing \(\geq\) 20% above individual baseline + 2 ng/mL per Valent 2021 criteria (Valent et al. 2021) (note: tryptase alone is insensitive — positive in only \(\sim\) 9% of POTS-MCAS overlap patients (Kohno et al. 2021); urinary mediators preferred)
- Clinical response to mast cell–directed therapy: \(\geq\) 30% improvement in validated symptom score (e.g., COMPASS-31) after 4-week empirical H1/H2 antihistamine trial (Conway et al. 2024)
Exclusion (secondary MCAS): Active IgE-mediated allergy with known allergen; systemic mastocytosis (if baseline tryptase persistently \(>\) 20 ng/mL, refer for bone marrow biopsy); hereditary alpha-tryptasemia (genetic test if baseline tryptase \(>\) 8 ng/mL).
If Present → Diagnosis: “ME/CFS with Mast Cell / Histaminergic Dysregulation”
No randomised controlled trial of mast cell stabilisation has been conducted in ME/CFS. The Steinberg 1996 terfenadine RCT in CFS was negative (Steinberg et al. 1996). Treatment recommendations below are extrapolated from MCAS, POTS-MCAS, and hEDS-MCAS populations and should be considered empirical. The evidence base for Tiers 2–3 is very low quality (expert consensus and case series only). A Mayo Clinic retrospective study (JACI 2026) found that none of 110 adults with hEDS/POTS and suspected MCAS met established diagnostic criteria, with 95% having unconfirmed MCAS labels — cautioning against overdiagnosis.
Treatment Implications:
Tier 1 — First line (weeks 1–4):
- Cetirizine 10 mg daily (H1 antihistamine; non-sedating)
- Famotidine 20 mg twice daily (H2 antihistamine)
- Low-histamine diet trial (4 weeks; eliminate fermented foods, aged cheeses, alcohol, long-cooked tomatoes)
- Trigger avoidance: heat, vigorous exercise, emotional stress, NSAIDs, opioids, specific foods
Tier 2 — Mast cell stabilizers (weeks 4–8 if partial response):
- Ketotifen 1–2 mg at bedtime (H1 antihistamine + mast cell stabilizer; first choice when sedation tolerable)
- Cromolyn sodium oral 100–200 mg four times daily before meals (GI-predominant symptoms; poorly absorbed, acts luminally)
- Quercetin 500 mg twice daily (natural mast cell stabilizer via HDAC inhibition of Fc\(\varepsilon\)RI signaling) (Folkerts et al. 2020)
Tier 3 — Specialist referral (weeks 8+):
- Omalizumab (anti-IgE monoclonal antibody): for IgE-driven component or refractory urticaria; specialist prescribing required
- Rule out systemic mastocytosis if tryptase persistently \(>\) 20 ng/mL
- Small fiber neuropathy workup if autonomic symptoms predominate (MCAS-SFN overlap documented in 80% of mast cell disorder patients (Novak et al. 2022))
Drug interactions: Ketotifen may increase the sedating effect of antihistamines, CNS depressants, and some antiemetics. Cromolyn has minimal systemic absorption and few interactions. Famotidine is generally well-tolerated but may interact with atazanavir and some antifungals.
ME/CFS-specific note: Mast cell mediators exacerbate preload failure via histamine-mediated vasodilation (Wirth and Scheibenbogen 2023). Domain 6 patients with co-occurring dysautonomia (Domain 4) should receive both treatments concurrently — treating only one domain leaves the other as a perpetuating factor. Start dose titration from lowest effective dose given common sensitivity in ME/CFS patients (starting dose: cetirizine 5 mg; famotidine 20 mg once daily rather than twice).
Prevalence: 16–25% of ME/CFS patients by two-cohort study (Rohrhofer et al. 2025) (estimates range 10–50% depending on diagnostic criteria applied); significantly higher rates when POTS is comorbid (Yao et al. 2025).
1.15 Hypothetical Phenotype Under Investigation: Viral-Immune-Metabolic Type
The “Viral-Immune-Metabolic” phenotype described below is hypothetical and unvalidated. It is based on:
- Single-case clinical observation extrapolation
- Mechanistic reasoning without controlled validation
- Limited anecdotal reports of cimetidine response
This phenotype concept requires rigorous validation in prospective cohort studies before clinical adoption. It should NOT be used for diagnosis or treatment selection outside research protocols.
Clinical observation in isolated cases has suggested a potential subset of patients whose symptom pattern and treatment response might indicate a specific pathophysiological cluster crossing multiple domains. This hypothetical phenotype is presented for research discussion only.
Proposed Phenotype Definition.
The “Viral-Immune-Metabolic” cluster (see Section Skeletal Asymmetry as a Subgroup-Defining Feature for detailed discussion) is characterized by:
- Post-infectious onset (EBV, HHV-6, or other herpesvirus)
- MCAS or histamine intolerance (HIT) comorbidity
- POTS/dysautonomia
- Strong response to amino acid supplementation
- Dramatic response to cimetidine (rare but distinctive)
Targeted Test Panel for Suspected Viral-Immune-Metabolic Cluster.
| Domain | Priority 1 Tests | Priority 2 Tests | Phenotype Indicator |
|---|---|---|---|
| Viral-Immune | EBV serology (VCA IgG/IgM, EBNA-1, EA-D), HHV-6 serology — note: VCA IgG/EBNA-1 IgG reflect remote infection, not current activity; VCA IgM may indicate recent primary or polyclonal activation; interpret separately (Section HSV Dormancy-Undormancy Probe — Structural Limitations) | HHV-6/EBV PCR, T cell exhaustion panel (PD-1, LAG-3) | Cimetidine response |
| Metabolic | Amino acid panel (serum), D-Ribose therapeutic trial | Lactate/pyruvate ratio, organic acids (urine) | Amino acid response |
| Mast Cell | Serum tryptase, plasma histamine, DAO activity | 24h urine N-methylhistamine, prostaglandin D2 | HIT/MCAS symptoms |
| Dysautonomia | Tilt test, lying/standing catecholamines | HRV analysis, QSART | POTS + MCAS coupling |
| Endothelial | Flow-mediated dilation, ADMA | L-Arginine/L-Citrulline therapeutic response | NO dysfunction |
Clinical Decision Tree.
If this phenotype is suspected:
- Cimetidine shows benefit → Prioritize viral serology (EBV/HHV-6) + amino acid panel
- Strong amino acid response → Prioritize intestinal permeability markers (Zonulin, LPS) + mitochondrial assessment
- POTS + MCAS both present → Prioritize dysautonomia subtyping (hyperadrenergic vs. neuropathic)
Treatment Approach (Hypothetical).
This treatment protocol requires physician supervision and cannot be safely self-implemented:
- Drug interaction monitoring: Cimetidine is a CYP3A4/CYP450 inhibitor affecting metabolism of many medications (warfarin, phenytoin, theophylline, benzodiazepines, beta-blockers, calcium channel blockers). Important: Ivabradine (used for POTS in Domain 4 co-management) is a CYP3A4 substrate — co-prescription with cimetidine markedly increases ivabradine plasma levels and bradycardia risk; avoid the combination or use with cardiology monitoring.
- Renal function assessment: Valacyclovir requires dose adjustment in renal impairment; accumulation can cause neurotoxicity
- Adverse effect monitoring: CNS effects (cimetidine), nephrotoxicity (antivirals), hypotension (histamine blockade)
- Laboratory monitoring: Renal function (creatinine, eGFR) before and during antiviral therapy; liver function tests; complete blood count
Do not attempt this protocol without medical consultation and ongoing physician oversight.
For confirmed Viral-Immune-Metabolic cluster:
- Foundation: Pacing + H1/H2 dual blockade (mast cell stabilization)
- Metabolic support: NAC 1800 mg/day, L-citrulline-malate 6–8 g/day, D-ribose 5 g TID
- If viral titers elevated: Consider antiviral trial (valacyclovir for EBV, valganciclovir for CMV/HHV-6)
- If cimetidine response: Continue cimetidine 200–400 mg BID (immunomodulation benefit)
- Reassess: 3-month follow-up with repeat amino acid panel and symptom tracking
This phenotype cluster is based on clinical observation and mechanistic reasoning, not validated clinical trials. The specific test panel and treatment sequence are proposed for systematic evaluation, not established standard of care. See Section Skeletal Asymmetry as a Subgroup-Defining Feature for detailed certainty assessment.
1.16 Multi-Label Diagnosis Example
Primary Diagnosis: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Biological Phenotype (Tier 2 Multi-Domain Assessment):
- \(checkmark\): Autoimmune component: GPCR autoantibodies \(\beta_2\)-adrenergic 12.5 U/mL (ref \(<\) 8), M3 muscarinic 9.2 U/mL (ref \(<\) 7)
- \(checkmark\): Mitochondrial dysfunction: Fasting lactate 2.8 mmol/L (ref \(<\) 2.0); 2-day CPET workload at VT decreased 35% on Day 2
- \(checkmark\): Neuroinflammatory component: Pressure pain thresholds 1.8 kg (ref \(>\) 4.0); photophobia requiring indoor sunglasses; phonophobia limiting social interaction
- \(checkmark\): Dysautonomia: POTS confirmed on tilt table (supine HR 65 bpm → standing HR 102 bpm at 8 minutes); HRV SDNN 18 ms (ref \(>\) 50)
- \(\\times\): Endothelial dysfunction: Not assessed (markers unavailable)
- \(\\times\): Mast cell / histaminergic dysregulation (Domain 6): Not assessed (episodic multi-system symptoms absent by history; empirical H1/H2 trial not yet performed)
Severity (Tier 3): Moderate (housebound 40% of time; can perform remote work 20 hours/week with careful pacing)
Progression Risk: HIGH—RED FLAGS present: ratcheting baseline over past 9 months (each crash leaves lower functional floor); recovery time lengthening from 3 days → 10 days for equivalent exertion
Treatment Plan:
- Foundation: Aggressive pacing (50% rule, heart rate monitoring <105 bpm)
- Dysautonomia (quick win, high accessibility): Fludrocortisone 0.1 mg daily, sodium 6 g/day, fluids 2.5 L/day, compression stockings
- Mitochondrial (quick win, high accessibility): CoQ10 300 mg, nicotinamide riboside 1000 mg, B-complex
- Neuroinflammation (quick win, high accessibility): Low-Dose Naltrexone (LDN) 3 mg at bedtime, light/sound environmental control
- Autoimmune (if accessible): Immunoadsorption or daratumumab candidate; pursue if no improvement after 6 months on above protocol
Reassessment: 3-month follow-up to evaluate response in each domain; adjust treatment based on which domains improve vs. persist ## Tier 3: Severity Classification and Progression Risk {#subsec-tier3}
Tier 3 classifies current functional severity and prospectively assesses risk of progression to severe disease. This enables appropriate resource allocation, guides intervention intensity, and identifies patients requiring emergency intervention.
1.17 Functional Severity Scale
Mild ME/CFS
- Can work or study at 50–80% of pre-illness capacity, though with significant difficulty
- Post-exertional malaise occurs after moderate exertion
- Recovery from PEM takes days to 1–2 weeks
- Can perform most activities of daily living independently
- Energy envelope is reduced but allows meaningful activity
- Appears functional to outside observers (“invisible illness”)
Moderate ME/CFS
- Reduced daily activity to <50% of pre-illness level
- Housebound 50% or more of the time
- Unable to work or study full-time; may work part-time with difficulty
- Post-exertional malaise triggered by minimal exertion
- Recovery from PEM takes weeks
- Requires extended rest periods daily
- Significant impairment in social and occupational function
Severe ME/CFS
- Mostly bedbound (>50% of waking hours)
- Can perform only minimal self-care activities (brief washing, feeding)
- Post-exertional malaise triggered by activities of daily living
- Cognitive impairment prevents reading, sustained conversation
- Sensory sensitivities may require dimmed environment, minimal sound
- Unable to leave home except for essential medical appointments
- Requires assistance with instrumental activities of daily living
Very Severe ME/CFS
- Bedbound continuously
- Unable to perform most self-care activities without assistance
- Profound sensitivity to light (requiring darkness), sound (requiring silence), touch
- May be unable to tolerate speaking or being spoken to
- Tube feeding may be required if swallowing is impaired
- Requires full-time care assistance
- Represents approximately 10% of severe ME/CFS cases (2–3% of total ME/CFS population)
1.18 Progression Risk Stratification
Patients meeting \(\geq\) 2 of the following RED FLAG criteria are at immediate risk of transitioning to severe, potentially irreversible disease and require emergency intervention:
RED FLAGS (Immediate Danger):
Ratcheting baseline: Each post-exertional crash leaves patient at a lower functional floor; baseline is trending downward over 6–12 months rather than returning to previous level. This corresponds to the rolling PEM phenomenon — overlapping crash cycles without full stabilization between episodes (Understanding the Urgency, rolling PEM concept).
Recovery time lengthening: PEM recovery now requires >2 weeks (previously required only days to 1 week)
Shrinking energy envelope: Activities that were safely within the energy envelope 6 months ago now trigger post-exertional malaise
New sensory sensitivities: Photophobia, phonophobia, or chemical sensitivities emerging or rapidly worsening
Cognitive decline: Word-finding difficulties, memory impairment, or inability to read/process information worsening (cognitive symptoms are most resistant to recovery) (Chu et al. 2019)
Forced overexertion: Patient cannot stop working or reduce activity due to financial necessity, despite clear evidence of deterioration (structural inability to pace)
Weight loss from energy insufficiency: Eating and food preparation have become too effortful; weight loss indicates severe energy depletion
Social withdrawal by necessity: Cannot tolerate visitors, phone calls, or any social interaction due to symptom exacerbation (not due to depression)
Emergency Action Protocol: Patients with HIGH RISK status require immediate intervention to prevent crossing the “point of no return” to irreversible severe ME/CFS:
Within 48 hours:
- Reduce all non-essential activity by 50%
- Implement aggressive horizontal rest (50–75% of waking hours)
- Cancel social commitments, request emergency work accommodation
Within 1 week:
- Physician visit for medical leave documentation
- Formal workplace accommodation request (reduced hours 50–75%, remote work, flexible schedule)
- Begin disability application process if accommodations denied or insufficient
Within 4–8 weeks:
- Achieve baseline stabilization: Goal of ZERO post-exertional malaise episodes for 4 continuous weeks
- This proves patient is within energy envelope
- Accept that functional capacity is very low during this period—this is temporary to prevent permanent severe disease
Rationale: Research and patient reports demonstrate that repeated post-exertional malaise episodes cause cumulative physiological damage: mitochondrial dysfunction accumulation (Wang et al. 2023) (Syed et al. 2025), endothelial dysfunction (Heng et al. 2025), neuroinflammation (Nakatomi et al. 2014), and immune exhaustion (Iu et al. 2024). There appears to be a threshold (anecdotally 5–10 severe crashes) beyond which recovery capacity is permanently impaired. The goal is to avoid severe crashes entirely, not merely to minimize them.
1.19 Critical Temporal Windows
Two temporal thresholds mark critical transitions in ME/CFS natural history (Maksoud et al. 2020):
6-Month Persistence Mark: If symptoms persist beyond 6 months without improvement, this indicates that normal homeostatic recovery mechanisms have failed and aberrant pathophysiology is becoming established. This marks the transition from “post-viral fatigue that might spontaneously resolve” to “ME/CFS requiring active intervention.”
2-Year Establishment Threshold: Around 2 years post-onset, ME/CFS transitions from early disease (hypermetabolic, potentially modifiable) to established disease (hypometabolic, potentially entrenched). This transition involves:
- Epigenetic changes altering gene expression patterns
- Immune exhaustion (CD8+ T cell exhaustion (Iu et al. 2024), NK cell dysfunction)
- Normalization of inflammatory markers despite ongoing dysfunction
- Brain structural changes visible on advanced imaging (Shan et al. 2020)
- Metabolic state shift from high (inefficient) energy expenditure to low energy production
Implication: The first 2 years represent a critical intervention window. Aggressive pacing, early biological phenotyping, and domain-targeted treatment during this period may prevent progression to established severe disease. After 2 years, reversal becomes substantially more difficult (though not impossible).
Clinical application: Patients diagnosed within 6 months of onset should be counseled on the criticality of aggressive pacing to prevent establishment. Patients approaching the 2-year mark should undergo comprehensive Tier 2 phenotyping to guide maximal intervention before the window closes. ## Implementation and Clinical Workflow {#subsec-implementation}
1.20 Minimum Diagnostic Workup (All Patients)
Tier 1 Clinical Assessment:
- Detailed history: onset pattern, post-exertional malaise characteristics, sleep quality, cognitive symptoms, autonomic symptoms, pain, sensory sensitivities
- Physical examination: orthostatic vital signs, neurological examination, tender point assessment
- Functional capacity assessment: Bell Disability Scale, SF-36, or equivalent
Objective Testing (if accessible):
- Two-day cardiopulmonary exercise testing (gold standard for PEM documentation)
- Tilt table testing or NASA Lean Test (dysautonomia assessment)
Basic Laboratory Testing (rule out exclusions):
- Complete blood count (CBC)
- Comprehensive metabolic panel (CMP)
- Thyroid-stimulating hormone (TSH), free T4
- Ferritin (low ferritin contributes to fatigue and restless legs)
- Antinuclear antibody (ANA)
- Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
- Vitamin D, vitamin B12
Sleep Study:
- Polysomnography to rule out obstructive sleep apnea (OSA) or upper airway resistance syndrome (UARS)
- OSA can mimic ME/CFS; treatment with CPAP dramatically improves symptoms in true OSA cases
- OSA and ME/CFS can coexist; treating comorbid OSA improves but does not cure ME/CFS
1.21 Advanced Phenotyping (Tier 2, If Resources Permit)
Autoimmune Domain:
- GPCR autoantibody panel (\(\beta_2\)-adrenergic, M3 muscarinic, M4 muscarinic)
- NK cell count and function assay
- Flow cytometry for plasma cell populations (CD38+CD138+)
Mitochondrial/Metabolic Domain:
- Heng 7-biomarker panel (when commercially available): AMP, ADP, VWF, fibronectin, thrombospondin-1, PDGF-BB, TGF-\(\beta\) 3
- Fasting lactate
- ATP profile (if specialized laboratory available)
Neuroinflammation Domain:
- Quantitative sensory testing (pressure pain thresholds)
- Skin biopsy for small fiber neuropathy (intraepidermal nerve fiber density)
Dysautonomia Domain:
- Tilt table testing (if not already performed)
- Heart rate variability analysis
- QSART or thermoregulatory sweat test (if available)
Mast Cell / Histaminergic Domain (Domain 6):
- Clinical history: episodic multi-system symptoms (\(\geq\) 2 organ systems)
- 24-hour urine N-methylhistamine + LTE4 + prostaglandin D2 metabolite (collect during symptomatic period; Mayo Clinic Labs) (Lee and Picard 2025)
- 4-week H1/H2 antihistamine empirical trial with validated symptom scoring (COMPASS-31) (Conway et al. 2024)
- Serum tryptase (acute, within 4 hours of flare) only if above urinary panel negative
Comorbidity Screening (Septad components):
- MCAS workup (Domain 6): serum tryptase, 24-hour urine N-methylhistamine + LTE4 + prostaglandin D2 metabolite; urinary panel preferred over tryptase alone (higher sensitivity) (Lee and Picard 2025) — see Section Multi-Domain Co-Occurrence Model for full criteria
- Hypermobility assessment: Beighton score
- If hEDS + progressive neurological symptoms: upright MRI for craniocervical instability screening
- Gastrointestinal: gastric emptying study, SIBO breath test (if prominent GI symptoms)
1.22 Treatment Prioritization Based on Phenotype
| Domain | Treatment Options | Risk Level | Access | Priority |
|---|---|---|---|---|
| Pacing | Activity management, heart rate monitoring | None | High | FIRST (always) |
| Dysautonomia | Salt, fluids, compression, fludrocortisone, midodrine | Low | High | SECOND (quick wins) |
| Mitochondrial | CoQ10, NR/NMN, B vitamins | Low | High | SECOND (quick wins) |
| Neuroinflam. | LDN, environmental modification | Low | High | SECOND (quick wins) |
| Autoimmune | Immunoadsorption, daratumumab, BC007 | Moderate-High | Very Low | THIRD (if accessible) |
| Endothelial | L-citrulline, omega-3, aspirin | Low | High | THIRD (experimental) |
| Mast Cell | H1/H2 antihistamines, low-histamine diet, ketotifen, cromolyn | Low | High | SECOND (if Domain 6 positive) |
Rationale:
- Foundation: Pacing is universal and non-negotiable—prevents cumulative damage regardless of biological phenotype
- Quick wins: High-accessibility, low-risk interventions (dysautonomia, mitochondrial, neuroinflammation) initiated simultaneously to address multiple domains
- Reassessment: At 3–6 months, evaluate response in each domain; persistent dysfunction despite accessible interventions justifies pursuit of high-intensity/low-accessibility treatments (immunoadsorption, daratumumab)
- Multi-target approach: Addresses multiple locks simultaneously, recognizing that single-domain interventions often fail due to reinforcement from untreated domains
This three-tiered diagnostic framework is a proposal, not an established or validated diagnostic system. Critical epistemic boundaries:
- No prospective study has tested whether the six biological domains (neuroinflammation, autoimmune, mitochondrial, dysautonomia, vascular-endothelial, mast cell/histaminergic) are clinically separable, whether their presence predicts treatment response, or whether multi-domain assessment improves outcomes over existing diagnostic criteria.
- The “rate-limiting domain” concept—that treatment response depends on which domain is the primary bottleneck—is a theoretical construct not yet supported by clinical data. The daratumumab responder/non-responder distinction is cited as supporting evidence, but the study was not designed to test this framework.
- Biomarker thresholds for domain positivity have not been established, validated, or replicated. Existing studies use different assays, populations, and cut-points, making standardisation premature.
- The framework’s reliance on the Heng 2025 7-biomarker panel (Heng et al. 2025) as validation of multi-system coordination rests on a single study that has not been independently replicated.
2 Research Implications and Validation Needs
This novel diagnostic framework generates testable predictions that should be validated in prospective studies:
Prediction: Patients with \(\geq\) 4 domains positive will have worse functional outcomes, longer illness duration, and lower treatment response rates than patients with 1–2 domains
- Test: Correlate number of positive domains with SF-36 Physical Function, Bell Disability Scale, work/school capacity, and hospitalization rates
Prediction: Multi-target interventions (treating all present domains) will produce superior outcomes compared to single-target interventions
- Test: Randomized controlled trial comparing CoQ10 monotherapy vs. CoQ10 + Low-Dose Naltrexone (LDN) + fludrocortisone (in patients with mitochondrial + neuroinflammatory + dysautonomia domains positive)
Prediction: The RED FLAG progression risk criteria (Tier 3) prospectively identify patients who will develop severe ME/CFS
- Test: Cohort study assessing RED FLAG status at enrollment, then tracking functional severity at 1 year and 2 years; calculate sensitivity/specificity of RED FLAG criteria for predicting progression to severe disease
Prediction: Treatment response to domain-specific interventions requires both (a) presence of dysfunction in that domain AND (b) that domain being rate-limiting (the bottleneck)
- Test: Measure all 6 domains → administer domain-specific treatment → identify responders vs. non-responders → retrospectively determine which baseline features predicted response
- Example: Daratumumab trial measuring GPCR autoantibodies, lactate, HRV, QST, VWF at baseline, then analyzing which baseline profile predicts 60% responder group vs. 40% non-responder group
Prediction: The Heng 7-marker panel achieves high diagnostic accuracy because it captures coordinated dysfunction across three systems (energy, immune, vascular), and symptom severity correlates with multi-system burden rather than single-marker elevation
- Test: Network analysis or partial least squares regression to determine if symptoms correlate with individual markers or require multi-marker patterns
Prediction: Early intervention (within the first 2 years) prevents establishment of refractory disease
- Test: Compare outcomes of patients receiving comprehensive Tier 2 phenotyping + multi-target treatment within 1 year of onset vs. those diagnosed/treated after 2+ years
- Ethical note: This should be observational (registry-based) rather than randomized, as withholding early treatment would be unethical if the hypothesis is correct
3 Comparison to Existing Criteria
Table Novel Diagnostic Framework: Entirely Unvalidated compares the novel biology-informed framework to established diagnostic criteria.
| Feature | Fukuda (1994) | Canadian (2003) | IOM (2015) | Novel Framework (2026) |
|---|---|---|---|---|
| PEM required | No | Yes | Yes | Yes (detailed criteria) |
| Duration | 6 months | 6 months | 6 months | 6 months (establishment threshold) |
| Biological phenotyping | No | No | No | Yes (6 domains) |
| Progression risk assessment | No | No | No | Yes (RED FLAGS) |
| Treatment stratification | No | No | No | Yes (domain-targeted) |
| Temporal windows | No | No | No | Yes (2-year critical window) |
| Recognizes heterogeneity | No | Partially | No | Yes (multi-label classification) |
| Objective biomarkers | No | Optional | Optional | Integrated (Tier 2) |
| Subgroup identification | No | No | No | Yes (co-occurrence model) |
The novel framework is compatible with existing criteria rather than contradictory:
- Tier 1 clinical criteria align with Canadian Consensus and IOM requirements
- Post-exertional malaise remains the mandatory hallmark (consistent with ICC, Canadian, IOM)
- 6-month duration threshold maintained (all modern criteria)
- Tier 2 and Tier 3 represent additions that do not invalidate previous diagnoses
Patients meeting Fukuda, Canadian Consensus, ICC, or IOM criteria will meet Tier 1 of the novel framework. The novel framework adds biological stratification (Tier 2) and risk assessment (Tier 3) that can be applied retroactively to existing cohorts. ## Clinical Advantages of the Novel Framework {#subsec-advantages}
Precision medicine: Biological phenotyping enables targeted treatment rather than trial-and-error
Explains treatment heterogeneity: Response variability attributed to different rate-limiting domains rather than “treatment doesn’t work”
Early intervention guidance: 6-month and 2-year thresholds identify critical windows for aggressive treatment
Progression prevention: RED FLAG criteria enable emergency intervention before irreversible severe disease
Research stratification: Multi-domain classification allows trials to enrich for patients with specific phenotypes (e.g., daratumumab trial selecting autoimmune-domain-positive patients)
Acknowledges complexity: Multi-label classification reflects biological reality (most patients have 3+ domains) rather than forcing heterogeneous patients into single category
Actionable at point of care: Tier 1 (clinical) immediately implementable; Tier 2 (biological) scalable as biomarkers become commercially available; Tier 3 (risk) requires only clinical observation